What did Novo Holdings pay for KabaFusion?

Novo Holdings acquired KabaFusion for $1.11B in 2022 (19.5x EBITDA). Target EBITDA was approximately $57.0M.

What does KabaFusion do?

KabaFusion is a pharmacy business.

What multiple did Novo Holdings pay for KabaFusion?

19.5x EBITDA, based on disclosed deal value of $1.11B and disclosed financials.

M&A TRANSACTION · 2022

KabaFusion acquired by Novo Holdings

$1.11B· 19.5x EBITDA

Target

KabaFusion

Acquirer

Novo Holdings

Disclosed financials at time of acquisition

Revenue

—

EBITDA

$57.0M

Deal Value

$1.11B

EV/EBITDA

19.5x

Context

This $1.11B acquisition of KabaFusion by Novo Holdings sits in the pharmacy sub-vertical. The 19.5x EBITDA multiple paid in 2022 can be compared against the population median for pharmacy transactions of similar size on our Pharmacy valuation hub.

Source

Data sourced from Press reporting. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own pharmacy

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the KabaFusion acquisition.

Citation: ExitValue.ai. (2022). KabaFusion acquired by Novo Holdings. https://exitvalue.ai/deals/kabafusion-acquired-by-novo-holdings-hc-2022-0060